Current issue
Journal content
Articles in press
Archive
About the Journal
About the Polish Annals of Medicine
Editorial Board
Open Access policy
Abstracting & indexing
Affiliated institutions
Contact
Instructions
Peer review process
Guide for authors
Publication ethics
Ethics and Patient Consent
User License
Usage of third party materials
Disclaimer
Reviewers
Guide for reviewers
List of reviewers
Review Form
RESEARCH PAPER
Immune polychemotherapy regimen choice in B-cell non-Hodgkin lymphoma of high and low malignancy based on the identification of the mutational c-myc and BCL 2 genes
1
Department of Management, Kazakh Research Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan
2
Center for Hemoblastosis and Bone Marrow Transplantation, Kazakh Research Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan
3
Center for Hematology and Bone Marrow Transplantation, Kazakh Research Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan
4
Laboratory of Cytogenetic and Moleculear Cytogenetic, Research Institute of Pediatrics and Pediatric Surgery, Almaty, Republic of Kazakhstan
5
Center for Morphological Research, Kazakh Research Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan
Submission date: 2021-01-15
Final revision date: 2021-02-05
Acceptance date: 2021-02-05
Online publication date: 2021-08-20
Corresponding author
Dilyara R. Kaidarova
Kazakh Research Institute of Oncology and Radiology, 480072, 91 Abai Ave., Almaty, Republic of Kazakhstan
Kazakh Research Institute of Oncology and Radiology, 480072, 91 Abai Ave., Almaty, Republic of Kazakhstan
Pol. Ann. Med. 2022;29(1):31–37
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The relevance of research is conditioned by the study of the gene expression profile for the identification of molecular subgroups of non-Hodgkin B-cell lymphomas (NHBCLs) in haematology.
Aim:
The aim of this research was to study the gene expression profile with the identification of molecular subgroups in patients with NHBCLs for personalised treatment.
Material and methods:
This paper is aimed at analysing the frequency and role of expression of c-myc, B-cell lymphoma 2 (BCL 2) proteins and the Ki 67 proliferative index in patients with NHBCLs and conducting personalised therapy to improve the immediate effectiveness and immediate treatment results.
Results and discussion:
The paper presents the results of the use of high-dose polychemotherapy (PCT) in 9 patients out of 80 with NHBCL during co-expression of the c-myc, BCL 2 mutational gene and with high values of the Ki 67 proliferative index. High-dose chemotherapy (HDCT) was performed according to the R+HyperCVAD scheme (6 courses) and hematopoietic stem cell (HSC) autotransplantation improved the immediate effectiveness of therapy, with a complete remission rate of 80% and an event-free survival of 28 months.
Conclusions:
The study of molecular genetic characteristics in 80 patients with NHBCLs revealed co-expression of the c-myc and BCL 2 mutational gene in 9 out of 80 patients, and they differed in the aggressive course, ‘poor’ response to therapy, which predetermined the use of high-dose PCT with transplantation of autologous stem cells.
The relevance of research is conditioned by the study of the gene expression profile for the identification of molecular subgroups of non-Hodgkin B-cell lymphomas (NHBCLs) in haematology.
Aim:
The aim of this research was to study the gene expression profile with the identification of molecular subgroups in patients with NHBCLs for personalised treatment.
Material and methods:
This paper is aimed at analysing the frequency and role of expression of c-myc, B-cell lymphoma 2 (BCL 2) proteins and the Ki 67 proliferative index in patients with NHBCLs and conducting personalised therapy to improve the immediate effectiveness and immediate treatment results.
Results and discussion:
The paper presents the results of the use of high-dose polychemotherapy (PCT) in 9 patients out of 80 with NHBCL during co-expression of the c-myc, BCL 2 mutational gene and with high values of the Ki 67 proliferative index. High-dose chemotherapy (HDCT) was performed according to the R+HyperCVAD scheme (6 courses) and hematopoietic stem cell (HSC) autotransplantation improved the immediate effectiveness of therapy, with a complete remission rate of 80% and an event-free survival of 28 months.
Conclusions:
The study of molecular genetic characteristics in 80 patients with NHBCLs revealed co-expression of the c-myc and BCL 2 mutational gene in 9 out of 80 patients, and they differed in the aggressive course, ‘poor’ response to therapy, which predetermined the use of high-dose PCT with transplantation of autologous stem cells.
FUNDING
None declared.
CONFLICT OF INTEREST
None declared.
REFERENCES (20)
1.
Misyurina AE, Misyurin VA, Baryakh EA, Kovrigina AM, Kravchenko SK. Role of c-MYC, BCL2, and BCL6 expression in pathogenesis of diffuse large B-Cell lymphoma. Klin Onkogematol. 2014;7(4):512–521 [in Russian].
2.
Frick M, Dörken B, Lenz G. New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma. Best Pract Res Clin Haematol. 2012;25(1):3–12. https://doi.org/10.1016/j.beha....
3.
Van Zelm MC, Szczepanski T, van der Burg M. Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion. J Exp Med. 2007;204(3):645–655. https://dx.doi.org/10.1084%2Fj....
4.
Liu YJ, Arpin C. Germinal center development. Immun Review. 1997;156:111–126. https://doi.org/10.1111/j.1600....
5.
Alencar AJ, Malumbres R, Kozloski GA. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res. 2011;17(12):4125–4135. https://doi.org/10.1158/1078-0....
6.
Montes-Moreno S, Martinez N, Sanchez-Espiridión B, et al. miRNA expression in diffuse large B-cells lymphoma treated with chemioimmunotherapy. Blood. 2011;118(4):1034–1040. https://doi.org/10.1182/blood-....
7.
Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(20):4021–4031. https://doi.org/10.1182/blood-....
8.
Klapper W, Stoecklein H, Zeynalova S, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Leukemia. 2008;22(12):2226–2229. https://doi.org/10.1038/leu.20....
9.
Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533–3537. https://doi.org/10.1182/blood-....
10.
Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360–3365. https://doi.org/10.1200/jco.20....
11.
Green TM, Nielsen O, de Stricker K, Xu-Monette ZY, Young KH, Møller MB. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol. 2012;36(4):612–619. https://doi.org/10.1097/pas.0b....
12.
Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–3459. https://doi.org/10.1200/jco.20....
13.
Guo M, Mao X, Ding X. Molecular genetics related to non-Hodgkin lymphoma. Open Life Scienc. 2016;11(1):86–90. https://doi.org/10.1515/biol-2....
14.
El Hussein S, Patel KP, Fang H, et al. Genomic and immunophenotypic landscape of aggressive NK-cell leukemia. Am J Surg Pathol. 2020;44(9):1235–1243. https://doi.org/10.1097/PAS.00....
15.
Zhang W, Yang L, Guan YQ, et al. Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma. BMC Cancer. 2020;20(1):714. https://doi.org/10.1186/s12885....
16.
Ngan HYS, Seckl MJ, Berkowitz RS, et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynecol Obstet. 2018;143(Suppl 2):79–85. https://doi.org/10.1002/ijgo.1....
17.
Grabala J, Grabala M, Onichimowski D, Grabala P. Assessment of the applicability of transthoracic lung ultrasound for diagnosing purulent lobar pneumonia: A case study. Pol Ann Med. 2020;27(2):174–177. https://doi.org/10.29089/2020.....
18.
Franco F, González-Rincón J, Lavernia J, et al. Mutational profile of primary breast diffuse large B-cell lymphoma. Oncotarget. 2017;8(61):102888–102897. https://doi.org/10.18632/oncot....
19.
Shah B, Shaikh MV, Chaudagar K, Nivsarkar M, Mehta A. D-limonene possesses cytotoxicity to tumor cells but not to hepatocytes. Pol Ann Med. 2019;26(2):98–104. https://doi.org/10.29089/2017.....
20.
Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. New Eng J of Med. 2018;378(15):1396–1407. https://doi.org/10.1056/NEJMoa....
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.